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INTRODUCTION
Migrants	 are	 a	 key	 population	 affected	 by	 HIV	 across	
Europe	[1].	Migrant	adults	diagnosed	with	HIV	in	Europe	
are	 more	 likely	 to	 have	 advanced	 disease	 with	 low	 CD4	
count	 and/or	 AIDS	 diagnoses	 at	 first	 presentation	 or	 at	
initiation	of	antiretroviral	therapy	(ART)	compared	with	





vention	 of	 vertical	 transmission	 services	 in	 Europe	 over	
the	 last	 two	 decades,	 fewer	 children	 born	 domestically	
have	 HIV,	 and	 an	 increasing	 proportion	 of	 children	 liv-
ing	with	HIV	in	Europe	in	recent	years	were	born	abroad,	
mostly	 in	 sub-	Saharan	 Africa	 [9,10].	 Understanding	 the	




agnosis	 but	 comparable	 immunological	 and	 virological	
outcomes	 on	 ART	 in	 those	 born	 in	 sub-	Saharan	 Africa	











































Results: Of	 2620	 children	 included	 across	 12	 European	 countries,	 56%	 were	
migrants.	 At	 ART	 initiation,	 migrant	 children	 were	 older	 than	 domestic-	born	
children	(median	6.1	vs.	0.9 years,	p < 0.001),	with	slightly	higher	proportions	
being	severely	immunocompromised	(35%	vs.	33%)	and	with	active	tuberculosis	







dren	 have	 virological	 and	 immunological	 outcomes	 at	 1  year	 of	 ART	 that	 are	
comparable	to	those	who	are	domestic-	born,	possibly	indicating	equity	in	access	
to	healthcare	 in	Europe.	However,	 there	was	 some	evidence	of	a	difference	 in	
AIDS-	free	survival,	which	warrants	further	monitoring.
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Migrant	 status	 was	 defined	 as	 having	 been	 born	 out-
side	 of	 the	 country	 of	 the	 cohort	 versus	 domestic-	born,	
and	 children	 with	 unknown	 migrant	 status	 were	 ex-
cluded.	This	analysis	was	restricted	to	cohorts	where	≥ 5%	
of	patients	were	migrants	(12	cohorts	of	16	were	included;	
excluded	 cohorts	 were	 from	 Romania,	 Russia,	Thailand,	







and	 (iii)	 among	 children	 AIDS-	free	 at	 the	 start	 of	 ART,	
AIDS-	free	survival	after	ART	initiation,	using	Cox	models.



















In	 multivariable	 analyses,	 estimates	 of	 the	 effect	 of	
migrant	 status	 were	 adjusted	 for	 the	 following	 potential	
confounders:	sex;	year	of	birth;	mode	of	HIV	acquisition;	





1990	 growth	 charts	 [14].	 Interactions	 between	 migrant	
status	 and	 year	 of	 birth,	 and	 non-	proportional	 hazards	




migrants	 born	 in	 sub-	Saharan	 Africa	 against	 those	 who	














endar	 years	 than	 domestic-	born	 children	 (77%	 vs.	 56%	





with	 data	 available,	 a	 larger	 proportion	 were	 severely	




in	 all	 children	 starting	 ART	 but	 was	 slightly	 more	 com-
mon	in	migrant	children	(2%	vs.	1%,	p < 0.001).
Non- suppressed VL and severe 





respectively	 (p  <  0.001),	 and	 73%	 and	 82%	 had	 a	 CD4	
measurement	(p < 0.001);	Table 2].
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T A B L E  1 	 Demographics,	characteristics	at	antiretroviral	therapy	(ART)	initiation	and	follow-	up	status,	by	migrant	status
Domestic- born (N = 1146; 44%) Migrant (N = 1474; 56%)
pn (%) or median (IQR)
Demographics
Country	of	current	residence











Female	sex 633	(55%) 752	(51%) 0.050
Ethnicity








< 2003 638	(56%) 1131	(77%) < 0.001
≥ 2003 508	(44%) 343	(23%)
Place	of	birth





N 916 1244 < 0.001
Median	(IQR) 0.8	(0.2–	3.2) 6.2	(2.8–	10.0)
Characteristics at ART initiation
Calendar	year




N 916 1244 0.001
Median	(IQR) 2.0	(0.6–	22.0) 3.9	(0.9–	26.4)
Age	(years)
Median	(IQR) 1.8	(0.3–	7.6) 8.2	(4.0–	12.0) < 0.001
(Continues)




for	 migrant	 children	 vs.	 domestic-	born,	 95%	 confidence	
interval	(CI):	0.56–	0.88,	p = 0.002].	However,	this	differ-






Among	 those	 with	 a	 CD4	 measurement	 available	 at	
1  year,	 similar	 proportions	 of	 migrant	 and	 domestic-	








AIDS- free survival after ART start





event.	 Among	 the	 remaining	 2173	 children	 who	 were	
AIDS-	free	 at	 ART	 initiation,	 120	 (6%;	 47	 domestic-	born	
Domestic- born (N = 1146; 44%) Migrant (N = 1474; 56%)
pn (%) or median (IQR)








Yes 131	(11%) 119	(8%) 0.001
No 602	(53%) 735	(50%)
Missing 413	(36%) 620	(42%)
Tuberculosis	disease 7	(1%) 36	(2%) < 0.001
AIDS	diagnosis 219	(19%) 210	(14%) 0.003
Initial	ART	regimen






Median	(IQR) 7.8	(4.1–	11.4) 6.2	(3.4–	9.2) < 0.001
Follow-	up	status







T A B L E  1 	 (Continued)
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free	 survival	 was	 94%	 (95%	 CI:	 93–	95%),	 with	 no	 differ-
ence	by	migrant	 status	 (log-	rank	 test	 p = 0.206)	 (Figure	

















living	 with	 HIV	 across	 Europe,	 with	 data	 on	 over	 2600	
children	 from	 12	 countries.	 Migrants	 in	 this	 study	 were	
predominantly	from	sub-	Saharan	Africa,	and	were	older	
at	 treatment	 initiation	 with	 a	 slightly	 higher	 proportion	




at	 1	 year	 after	 ART	 initiation	 were	 similar	 between	 mi-




tients	 from	 which	 were	 included	 here),	 which	 reported	
no	difference	by	migrant	status	in	long-	term	immune	and	
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of	a	trend	towards	increased	risk	of	AIDS	or	death	among	
migrant	children	who	were	AIDS-	free	at	ART	initiation,	
indicating	 a	 possible	 difference	 in	 longer-	term	 clinical	




move	 into	young	adulthood	and	 transition	 to	adult	HIV	
care	 [17].	 In	 addition,	 tuberculosis	 represented	 a	 higher	
proportion	of	the	reported	AIDS	events	among	migrants,	
highlighting	 the	need	 for	 screening	and	 treatment	of	 la-
tent	tuberculosis	infection	in	this	population.
Many	 adult	 HIV	 studies	 in	 western	 Europe	 have	 re-





and	 heterosexual	 men,	 but	 higher	 risk	 of	 death	 was	 ob-





populations.	 A	 study	 of	 pregnant	 women	 with	 HIV	 in	
Europe	also	reported	a	higher	risk	of	 late	HIV	diagnosis	


































This	 article	 is	 based	 on	 MKV's	 dissertation	 in	 part	 ful-
filment	 of	 the	 requirements	 for	 the	 degree	 of	 an	 MSc	
in	 Epidemiology	 at	 the	 London	 School	 of	 Hygiene	 and	
Tropical	Medicine	in	2016.
Project team	 (ordered	 by	 contribution,	 apart	 from	
last	 author):	 Elizabeth	 Chappell	 (EPPICC	 statistician);	
Malte	Kohns	Vasconcelos;	Ruth	Goodall	(EPPICC	senior	
statistician);	 Luisa	 Galli	 (Italian	 Register	 for	 HIV	 infec-












rest	 of	 Spain	 cohort,	 Spain);	 Josiane	 Warszawski	 (French	
Perinatal	 Cohort	 Study,	 France);	 Vana	 Spolou	 (Greece	
Cohort,	 Greece);	 Elena	 Chiappini,	 Elisabetta	 Venturini	
(Italian	Register	for	HIV	infection	in	children,	Italy);	Filipa	
Prata	(Hospital	de	Santa	Maria/CHULN,	Lisbon,	Portugal);	
Christian	 Kahlert	 (Swiss	 Mother	 and	 Child	 HIV	 Cohort	
Study,	 Switzerland);	 Magdalena	 Marczynska	 (Polish	 pae-
diatric	cohort,	Poland);	Laura	Marques	(Centro	Hospitalar	
do	 Porto,	 Portugal);	 Lars	 Naver	 (Karolinska	 University	
Hospital,	 Stockholm,	 Sweden);	 Claire	 Thorne	 (European	
Collaborative	 Study);	 Diana	 M.	 Gibb,	 Carlo	 Giaquinto	
(EPPICC/Penta	Foundation)
EPPICC/PENTA Co- ordinating Team:	 Elizabeth	
Chappell,	 Intira	 Jeannie	 Collins,	 Siobhan	 Critchton,	
Charlotte	 Duff,	 Carlo	 Giaquinto,	 Ruth	 Goodall,	 Daniel	
Gomezpena,	Charlotte	Jackson,	Ali	Judd,	Rebecca	Lundin,	
Laura	 Mangiarini,	 Edith	 Milanzi,	 Alessandra	 Nardone,	
Claire	Thorne
Collaborating cohorts
Belgium:	 Hopital	 St	 Pierre	 Cohort,	 Brussels:	 Tessa	
Goetghebuer,	MD,	PhD;	Marc	Hainaut,	MD	PhD;	Evelyne	
Van	 der	 Kelen,	 research	 nurse;	 Marc	 Delforge,	 data	
manager.
France:	 French	 Perinatal	 Cohort	 Study/Enquête	
Périnatale	 Française,	 ANRS	 EPF-	CO10.	 Coordinating	
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center,	 INSERM	 U1018,	 team	 4:	 Josiane	 Warszawski,	
Jerome	Le	Chenadec,	Elisa	Ramos,	Olivia	Dialla,	Thierry	
Wack,	 Corine	 Laurent,	 Lamya	 Ait	 si	 Selmi,	 Isabelle	
Leymarie,	Fazia	Ait	Benali,	Maud	Brossard,	Leila	Boufassa.
Participating	 sites	 (hospital	 name,	 city,	 main	 in-
vestigator):	 Hôpital	 Louis	 Mourier,	 Colombes,	 Dr	
Corinne	 Floch-	Tudal;	 Groupe	 Hospitalier	 Cochin	
Tarnier	Port-	Royal,	PARIS,	Dr	Ghislaine	Firtion;	Centre	
Hospitalier	 Intercommunal,	 Creteil,	 Dr	 Isabelle	 Hau;	
Centre	 Hospitalier	 Général,	 Villeneuve	 Saint	 Georges,	
Dr	 Anne	 Chace;	 Centre	 Hospitalier	 Général-	 Hôpital	
Delafontaine,	 Saint-	Denis,	 Dr	 Pascal	 Bolot;	 Groupe	
Hospitalier	 Necker,	 Paris,	 Pr	 Stéphane	 Blanche;	
Centre	 hospitalier	 Francilien	 Sud,	 Corbeil	 Essonne,	 Dr	
Michèle	 Granier;	 Hôpital	 Antoine	 Béclère,	 Clamart,	 Pr	
Philippe	Labrune;	Hôpital	Jean	Verdier,	Bondy,	Dr	Eric	
Lachassine;	 Hôpital	 Trousseau,	 Paris,	 Dr	 Catherine	




Bordeaux,	 Dr	 Camille	 Runel-	Belliard;	 CHU	 Paule	 de	
Viguier,	 Toulouse,	 Dr	 Joëlle	 Tricoire;	 CHU	 Hôpital	




Caen,	 Pr	 Jacques	 Brouard;	 Institut	 d'Hématologie	 et	
Oncologie	 Pédiatrique,	 Lyon,	 Dr	 Kamila	 Kebaili;	 CHU	





Italy:	 Italian	 Register	 for	 HIV	 infection	 in	 Children.	
Coordinators:	Maurizio	de	Martino,	Luisa	Galli	(Florence),	
Pier	Angelo	Tovo,	Clara	Gabiano	(Turin).	Participants:	Ines	
Carloni	 (Ancona),	 Domenico	 Larovere	 (Bari),	 Francesco	
Baldi,	Angela	Miniaci,	Andrea	Pession	(Bologna)	Raffaele	
Badolato	(Brescia),	Grazia	Pantò	(Catania),	Elisa	Anastasio	
(Catanzaro),	 Carlotta	 Montagnani,	 Elisabetta	 Venturini,	
Leila	 Bianchi	 (Florence),	 Alessandra	 Allodi,	 Antonio	
Di	 Biagio,	 Sara	 Grignolo	 (Genua),	 Vania	 Giacomet,	
Paola	 Marchisio,	 Giuseppe	 Banderali,	 Claudia	Tagliabue	
(Milan),	 Monica	 Cellini	 (Modena),	 Eugenia	 Bruzzese,	
Pasquale	Di	Costanzo,	Andrea	Lo	Vecchio	(Naples),	Carlo	




(Rome),	 Letizia	 Cristiano	 (Taranto),	 Antonio	 Mazza	







Clinical centres (paediatric care)
Emma	 Kinderziekenhuis	 (Amsterdam	 UMC,	 AMC	
site):	 HIV- treating physicians:	 M.	 van	 der	 Kuip,	 DPajkrt	
H.J.	 Scherpbier.	 HIV nurse consultants:	 C.	 de	 Boer,	




A.M.C.	 van	 Rossum,	 C.L.	 Vermont.	 HIV nurse consul-
tants:	 L.C.	 van	 der	 Knaap,	 EVisser.	 HIV clinical virolo-
gists/chemists:	 C.A.B.	 Boucher,	 M.P.G.	 Koopmans,	 J.J.A.	
van	Kampen.	Radboudumc,	Nijmegen:	HIV- treating phy-
sicians:	 S.S.V.	 Henriet,	 M.	 K.	 van	 Aerde.	 HIV nurse con-
sultants:	 RStrik-	Albers.	 HIV clinical virologists/chemists:	
JRahamat-	Langendoen,	F.F.	Stelma.	HIV clinical pharma-
cology consultant:	DBurger.	Universitair	Medisch	Centrum	
Groningen/Beatrix	 Kinderziekenhuis,	 Groningen:	 HIV- 
treating physicians:	 E.H.	 Schölvinck,	 A.R.	 Verhage.	 HIV 
nurse consultants:	 Hde	 Groot-	de	 Jonge.	 HIV clinical vi-
rologists/chemists:	 H.G.M.	 Niesters,	 C.C.	 van	 Leer-	Buter,	
MKnoester.	Wilhelmina	Kinderziekenhuis,	UMC	Utrecht,	
Utrecht:	HIV- treating physicians:	L.J.	Bont,	S.P.M.	Geelen,	
Y.G.T.	 Loeffen,	 T.F.W.	 Wolfs.	 HIV nurse consultants:	 N.	
Nauta.	 HIV clinical virologists/chemists:	 RSchuurman,	
L.M.	Hofstra,	A.M.J.	Wensing.
Coordinating centre
Director:	 PReiss.	 Deputy director:	 SZaheri.	 Data anal-
ysis:	 A.C.	 Boyd,	 D.O.	 Bezemer,	 A.I.	 van	 Sighem,	 C.	 Smit,	
F.W.M.N.	Wit.	Data management and quality control:	M.M.J.	
Hillebregt,	 T.J.	 Woudstra.	 Data monitoring:	 DBergsma,	 L.	




L.	 Munjishvili,	 F.	 Paling,	 B.	 Peeck,	 C.	 Ree,	 R.	 Regtop,	 Y.	
Ruijs,	M.	Schoorl,	P.	Schnörr,	E.	Tuijn,	L.	Veenenberg,	K.M.	
Visser,	E.C.	Witte.	Patient registration:	YRuijs.
Poland:	 Polish	 paediatric	 cohort:	 Head	 of	 the	 team:	
Prof	 Magdalena	 Marczyńska,	 MD,	 PhD.	 Members	 of	
the	 team:	 Jolanta	 Popielska,	 MD,	 PhD;	 Maria	 Pokorska-	
Śpiewak,	 MD,	 PhD;	 Agnieszka	 Ołdakowska,	 MD,	 PhD;	
Konrad	Zawadka,	MD,	PhD;	Urszula	Coupland,	MD,	PhD.	
Administration	assistant:	Małgorzata	Doroba.	Affiliation:	
Medical	 University	 of	 Warsaw,	 Poland,	 Department	 of	
Children's	 Infectious	 Diseases;	 Hospital	 of	 Infectious	
Diseases	in	Warsaw,	Poland.
Portugal:	 Centro	 Hospitalar	 Universitário	 do	 Porto:	
Laura	Marques,	Carla	Teixeira,	Alexandre	Fernandes.
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Portugal:	 Hospital	 de	 Santa	 Maria/CHULN:	 Filipa	
Prata.
Spain:	 CoRISPE-	cat,	 Catalonia:	 CoRISPE-	cat	 receives	
financial	 support	 from	 the	 Instituto	 de	 Salud	 Carlos	 III	
through	 the	 Red	 Temática	 de	 Investigación	 Cooperativa	
en	 Sida	 (grant	 numbers	 RED	 RIS	 RD06/0006/0035	
yRD06/0006/0021).	 Members:	 Hospital	 Universitari	
Vall	 d'Hebron,	 Barcelona	 (Pere	 Soler-	Palacín,	 Maria	





Arnau	 de	Vilanova,	 Lleida	 (Teresa	Vallmanya),	 Hospital	
Universitari	 Joan	 XXIII,	 Tarragona	 (Olga	 Calavia),	
Consorci	Sanitari	del	Maresme,	Mataró	(Lourdes	García),	
Hospital	General	de	Granollers	 (Maite	Coll),	Corporació	
Sanitària	 Parc	 Taulí,	 Sabadell	 (Valentí	 Pineda),	 Hospital	
Universitari	 Sant	 Joan,	 Reus	 (Neus	 Rius),	 Fundació	
Althaia,	 Manresa	 (Núria	 Rovira),	 Hospital	 Son	 Espases,	
Mallorca	(Joaquín	Dueñas)	and	Hospital	Sant	Joan	de	Déu,	
Esplugues	(Clàudia	Fortuny,	Antoni	Noguera-	Julian).
Spain:	 CoRISPE-	S	 and	 Madrid	 cohort:	 María	 José	
Mellado,	 Luis	 Escosa,	 Milagros	 García	 Hortelano,	 Talía	










Penín	 (Hospital	 Universitario	 Príncipe	 de	 Asturias	 de	
Alcalá	 de	 Henares,	 Madrid);	 Jorge	 Martínez	 (Hospital	
Infantil	Universitario	Niño	Jesús,	Madrid);	Katie	Badillo	
(Hospital	Universitario	de	Torrejón,	Madrid);	Eider	Oñate	





Candelaria,	 Tenerife);	 Mónica	 Garzón,	 Vicente	 Román	
(Hospital	 General,	 Lanzarote);	 Raquel	 Angulo	 (Hospital	
de	Poniente	de	El	Ejido,	Almería);	Olaf	Neth,	Lola	Falcón	
(Hospital	 Universitario	Virgen	 del	 Rocío,	 Sevilla);	 Pedro	
Terol	 (Hospital	 Universitario	 Virgen	 de	 la	 Macarena,	
Sevilla);	Juan	Luis	Santos	(Hospital	Universitario	Virgen	
de	las	Nieves,	Granada);	David	Moreno	(Hospital	Regional	
Universitario	 Carlos	 Haya,	 Málaga);	 Francisco	 Lendínez	
(Complejo	 Hospitalario	 Torrecárdenas,	 Almería);	
Estrella	 Peromingo	 (Hospital	 Universitario	 Puerta	 del	
Mar,	 Cádiz);	 José	 Uberos	 (Hospital	 Clínico	 San	 Cecilio,	
Granada);	 Beatriz	 Ruiz	 (Hospital	 Universitario	 Reina	
Sofía	 de	 Córdoba);	 Ana	 Grande	 (Complejo	 Hospitalario	
Universitario	 Infanta	 Cristina,	 Badajoz);	 Francisco	 José	
Romero	 (Complejo	 Hospitalario,	 Cáceres);	 Carlos	 Pérez	
(Hospital	de	Cabueñes,	Asturias);	Miguel	Lillo	(Complejo	
Hospitalario	 Universitario,	 Albacete);	 Begoña	 Losada	
(Hospital	Virgen	de	la	Salud,	Toledo);	Mercedes	Herranz	
(Hospital	Virgen	 del	 Camino,	 Navarra);	 Matilde	 Bustillo	
(Hospital	 Universitario	 Miguel	 Servet,	 Zaragoza);	 Pilar	
Collado	 (Hospital	 Clínico	 Universitario	 Lozano	 Blesa,	
Zaragoza);	José	Antonio	Couceiro	(Complejo	Hospitalario	
Universitario,	 Pontevedra);	 Leticia	 Vila	 (Complejo	
Hospitalario	Universitario,	La	Coruña);	Consuelo	Calviño	
(Hospital	Universitario	Lucus	Augusti,	Lugo);	Ana	Isabel	
Piqueras,	 Manuel	 Oltra	 (Hospital	 Universitario	 La	 Fe,	
Valencia);	 César	 Gavilán	 (Hospital	 Universitario	 de	 San	
Juan	de	Alicante,	Alicante);	Elena	Montesinos	(Hospital	
General	Universitario,	Valencia);	Marta	Dapena	(Hospital	




Santiago	 Alfayate,	 Ana	 Isabel	 Menasalvas	 (Hospital	
Universitario	 Virgen	 de	 la	 Arrixaca,	 Murcia);	 Yolanda	
Ruiz	 del	 Prado	 (Complejo	 Hospitalario	 San	 Millán-	San	
Pedro,	 la	 Rioja)	 and	 Paediatric	 HIV-	BioBank	 integrated	
in	 the	 Spanish	 AIDS	 Research	 Network	 and	 collaborat-
ing	Centers.	Financial	support	for	CoRISpeS	and	Madrid	
Cohort	was	provided	by	the	Instituto	de	Salud	Carlos	III	




Sweden:	 Karolinska	 University	 Hospital,	 Stockholm,	
The	Swedish	InfCareHIV	cohort	(Lars	NavérNavér,	Sandra	
Soeria-	Atmadja,	Erik	Belfrage,	Vendela	Hagås).
Switzerland:	Members of the Swiss HIV Cohort Study 
(SHCS) and the Swiss Mother and Child HIV Cohort 






Council"),	 Hasse	 B,	 Hirsch	 HH,	 Hoffmann	 M,	 Hösli	 I,	
Huber	M,	Kahlert	CR	(Chairman	of	the	Mother	&	Child	
Substudy),	 Kaiser	 L,	 Keiser	 O,	 Klimkait	 T,	 Kottanattu	




Scherrer	 AU	 (Head	 of	 Data	 Centre),	 Schmid	 P,	 Speck	





the	 framework	 of	 the	 Swiss	 HIV	 Cohort	 Study,	 sup-
ported	by	the	Swiss	National	Science	Foundation	(grant	
#177499).
UK	 &	 Ireland:	 Collaborative	 HIV	 Paediatric	 Study	
(CHIPS):	CHIPS	is	funded	by	the	NHS	(London	Specialised	
Commissioning	Group)	and	has	received	additional	sup-
port	 from	 Abbott,	 Boehringer	 Ingelheim,	 Bristol-	Myers	




CHIPS	 Steering	 Committee:	 Hermione	 Lyall	 (chair),	
Alasdair	 Bamford,	 Karina	 Butler,	 Katja	 Doerholt,	 Conor	
Doherty,	 Caroline	 Foster,	 Ian	 Harrison,	 Julia	 Kenny,	
Nigel	 Klein,	 Gillian	 Letting,	 Paddy	 McMaster,	 Fungai	
Murau,	 Edith	 Nsangi,	 Katia	 Prime,	 Andrew	 Riordan,	
Fiona	Shackley,	Delane	Shingadia,	Sharon	Storey,	Gareth	
Tudor-	Williams,	 Anna	 Turkova,	 Steve	 Welch.	 MRC	
Clinical	Trials	 Unit:	 Intira	 Jeannie	 Collins,	 Claire	 Cook,	




Hospitals	 participating	 in	 CHIPS	 in	 2019/20:	
University	 Hospitals	 Birmingham	 NHS	 Foundation	
Trust,	 Birmingham:	 L	 Thrasyvoulou,	 S	 Welch;	 Brighton	








Rayyah,	 N	 Klein,	 A	 Bamford,	 D	 Shingadia;	 Oxford	




NHS	 Trust,	 Leicester:	 S	 Bandi,	 E	 Percival;	 Luton	 and	
Dunstable	 Hospital	 NHS	 Foundation	 Trust,	 Luton:	 M	






J	 Daniels,	 Y	 Lees;	 Northampton	 General	 Hospital	 NHS	




L	 Cliffe,	 S	 Southall;	 Portsmouth	 Hospitals	 NHS	 Trust,	
Portsmouth:	 A	 Freeman;	 Raigmore	 Hospital,	 Inverness:	
H	 Freeman;	 Royal	 Belfast	 Hospital	 for	 Sick	 Children,	
Belfast:	S	Christie;	Royal	Berkshire	NHS	Foundation	Trust,	
Reading:	A	Gordon;	Royal	Children's	Hospital,	Aberdeen:	
D	 Rosie	 Hague,	 L	 Clarke;	 Royal	 Edinburgh	 Hospital	 for	
Sick	 Children,	 Edinburgh:	 L	 Jones	 L	 Brown;	 Royal	 Free	
NHS	Foundation	Trust,	London:	M	Greenberg;	Alder	Hey	
Children's	 NHS	 Foundation	 Trust,	 Liverpool:	 C	 Benson,	
A	 Riordan;	 Sheffield	 Children's	 NHS	 Foundation	 Trust,	
Sheffield:	 L	 Ibberson,	 F	 Shackley;	 University	 Hospital	
Southampton	 NHS	 Foundation	 Trust,	 Southampton:	 S	
Patel,	 J	 Hancock;	 St	 George's	 University	 Hospitals	 NHS	
Foundation	 Trust,	 London:	 K	 Doerholt,	 K	 Prime,	 M	
Sharland,	S	Storey;	Imperial	College	Healthcare	NHS	Trust,	
London:	EGH	Lyall,	C	Foster,	P	Seery,	G	Tudor-	Williams,	
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